MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction

Lili Ren 1, Shizhen Chen 1, Haidong Li, Zhiying Zhang, Jianping Zhong, Maili Liu, Xin Zhou *

Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan 430071, China

Abstract

Liposomes are effective drug delivery systems that can be functionalized with imaging contrast agents, providing both diagnosis and monitoring of disease treatment. Here we describe the design of a theranostic liposomal drug delivery system whose biodistribution can be real time imaged by contrast enhanced MRI and can achieve tandem chemotherapy drug delivery. Because $T_1$ relaxation of MRI depends upon the chemical structure of contrast agent as well as its interaction with neighbor environment, we rationally designed a functional liposome for in vivo $T_1$ enhanced MRI. The liposome shows a 36-fold higher $T_1$ relaxation rate over the commercial MRI contrast agent Omniscan® and a long circulation time up to 300 min in vivo. Moreover, the multifunctional liposome carries both hydrophobic and hydrophilic chemotherapeutic drugs, can synergistically enhance therapeutic effects of multiple drugs and selectively deliver them to lung tumors, leading to lower doses, toxicity and sustained release. The nanoparticles, which exhibit favorable biodistributions to tumors, offer new possibilities for the simultaneous delivery of more than one drug and the evaluation of therapeutic response in vivo by $T_1$ enhanced MRI.

Statement of Significance

Cancer cells invoke different mechanisms to resist cancer therapies, particularly when delivering a single agent in a given therapy. The combination of two (or more) thermotherapy agents provides a promising way to circumvent such situations of drug resistance, due to a favorable synergistic effect that "tricks" the drug resistance mechanism. However, challenges to the simultaneous delivery of two drugs prevail, especially with regards to the simultaneous delivery of hydrophobic and hydrophilic drugs. Furthermore, non-invasive in vivo imaging of drug distribution enables the real-time monitoring and prediction of therapeutic responses to treatment.

In this study, we rationally designed a theranostic liposomal drug delivery system whose biodistribution can be imaged via $T_1$-weighted MRI in real-time and can achieve tandem chemotherapy drug delivery. This original study will be of considerable use to the wider drug delivery community.

1. Introduction

Lung cancer is the leading cause of cancer death worldwide [1–4]. Non-small-cell lung cancer (NSCLC) accounts for over 80% of all lung cancer death cases. Despite the introduction of promising new chemotherapeutic agents for lung cancer, the average patient five-year survival rate remains low (5–15%) and this rate has persisted for decades [2,5,6]. These discouraging statistics are due, in part, to the lack of suitable drug delivery systems. Conventional drug delivery approaches neither deliver nor maintain sufficiently high drug concentrations at the site of solid lung tumors, leading to a lack of efficacy at treating the tumor, as well as adverse effects to the surrounding healthy tissues. Recent advances in chemotherapy and targeted therapy provide new treatment options for this disease. Indeed, current research efforts at treating NSCLC have focused on the precise intracellular delivery of drugs and diagnostic agents to selected target cell populations [7–10].

On the other hand, cancer cells invoke different mechanisms to resist cancer therapies, particularly in single agent administration.

http://dx.doi.org/10.1016/j.actbio.2016.02.011
1742-7061 © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
This seriously weakens the efficacy of anticancer drugs. Combination regimens may change this awkward situation. Paclitaxel (PTX) and carboplatin (CBP) are two established anticancer drugs [1,3,5,11–13]. When used together, they have been shown to result in a more effective strategy for treating advanced NSCLC. Although this doublet chemotherapy looks promising for NSCLC, there are still serious side effects, including nephrotoxicity, myelotoxicity, neurotoxicity, vomiting and nausea [3,14]. Drugs loaded in one particle with controlled manner may overcome these obstacles. The concept of dual drug-loaded liposome was investigated by little researches. A phase I study of a novel liposome with cytarabine and daunorubicin for patients with refractory acute leukemia was conducted and followed by a subsequent phase II trial. The phase II trial is currently underway [15]. Additional dual drug-loaded liposomes, irinotecan/floxuridine and irinotecan/cisplatin, were successfully developed to treat colorectal cancer and small cell lung cancer, respectively [16,17]. These drugs are all hydrophobic. Based on our former studies of PTX-loaded liposomal system, here we look forward to design a more compatible PTX-CBP-loaded liposome [18].

To minimize side effects or damage to healthy tissue while achieving an effective therapy, liposomes, which have a hydrophilic core and a hydrophobic bilayer, are promising carriers for delivery of PTX, DDP (cisplatin, an analogue of CBP) and CBP [7,19–26]. The preparation of PTX, solubilized in a mixture of Cremophor EL (polyethoxylated castor oil) and ethanol to overcome its poor solubility in water, can give rise to undesirable effects [19–22]. It is already known that the liposomal PTX can overcome this obstacle and is beneficial to the phase II study of NSCLC patients with malignant pleural effusions [27]. Furthermore, liposomal drug delivery can be targeted to tissues in a selective manner, reducing the dose required and the off-target toxicity [24]. The folate receptor-targeted CBP liposome has been shown to improve the drug potency and reduce the toxicity in metastatic ovarian cancer [28]. A ligand-modified, PTX-loaded liposome could be targeted to mitochondria, enhancing anti-tumor efficacy and reducing non-specific toxicity [29].

Recently, research has focused on the development of nanonconstruct tools that incorporate multiple functionalities including capabilities for multimodal imaging to enable the simultaneous diagnosis and therapy. MRI-guided drug delivery combining cancer therapy and detection can help monitor the clinical response in real-time and could lead to personalized therapies [30,31]. Commonly used \( T_1 \) contrast agents, such as Gd chelates, can shorten the spin-lattice relaxation time of nearby protons and yield positive \( T_1 \) contrast in \( T_1 \)-weighted MRI images. The seven unpaired electrons of Gd (III) create a strong local magnetic field that fluctuates at the rate at which the complex tumbles in solution. In order to improve \( T_1 \) relaxation, we have rationally designed a functional liposome for optimization of the relaxation and circulation time. Additionally, Gd chelates are biodistributed non-specifically and rapidly eliminated from the body [30]. Liposomes that are loaded with suitable contrast agents can help overcome these obstacles, leading to an improved MRI readout [31–33].

In this article, a new and universal combination treatment drug delivery system was developed for targeting NSCLC (Fig. 1), including both hydrophilic (CBP) and hydrophobic (PTX) drugs. The targeted peptide \( c(RGDyK) \) tethered to the surface of the liposome, is recognized by \( \alpha_v\beta_3 \) integrin receptor, which is overexpressed in many tumor cells. Receptor-mediated liposome endocytosis and subsequent release of the contents could enhance the diagnostic and therapeutic results upon administration [7,8,34–36]. The cancer cells targeted with the multifunctional liposomes were readily detectable by MRI and confocal microscopy. Furthermore, the MRI-guided liposome showed great cancer-targeting efficiency and thus great potential to improve the lung cancer imaging and therapy and the outcomes of cancer patients.

### 2. Materials and methods

#### 2.1. Liposome preparation

The peptide-lipid conjugates \( c(RGDyK)-PEG2000-DSPE \) were synthesized using cross-linker 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC, Medpep, China) and N-hydroxysuccinimide (NHS, Sigma, USA) first [37,38]. COOH-PEG2000-DSPE (NANOCs, USA) was dissolved in PBS buffer. Then appropriate amounts of NHS and EDC were added. After incubation at room temperature for 30 min, \( c(RGDyK) \), (GL Bioche, China) was added, followed by 10 h incubation. Excess unreacted peptides were removed by dialysis (2000 D). The conjugated lipid was then lyophilized for the following procedures.

Dual drug-loaded liposome (Gd-DTPA-CBP) was prepared by the thin film hydration method, followed by membrane extrusion [7,17,37,39]. 15 mg of lipids, DSPC (Corden Pharma, Switzerland), DSPG (Corden Pharma, Switzerland), MPEG-2000-DSPE (Corden Pharma, Switzerland) and \( c(RGDyK)-PEG2000-DSPE \) at a molar ratio of 7:2:1:0.5, were mixed and dissolved in 1 mL chloroform/methanol/water (1:1:0.3, v/v/v). PTX (Shyuanye, China) was added to the lipid solution at a molar ratio of 1:30 (drug to lipid). The solution was dried in vacuum to form a film and placed under high vacuum overnight. The film was then hydrated with 100 mM Gd-DTPA-BMA (Chemlin, China) and 0.01 mM CBP (Adamas, China) to form multimellar vesicles. These vesicles were sonicated in water bath for 10 min and subsequently extruded 10 times through a 0.2-μm pore size filters. The free PTX was excluded by centrifugation for 10 min at 2000 rpm. The exterior buffer of the liposome was exchanged by 1% glucose via dialysis (10 kD) for 4 h. followed by lyophilization for use [29,31,40].

Rhodamine-labeled liposome (Rh-L), composed of DSPC, DSPG, MPEG-2000-DSPE, \( c(RGDyK)-PEG2000-DSPE \) and Rhod-DMPE (Avanti, USA) at the molar ratio of 7:2:1:0.5:0.2, was prepared using a method similar to that described above. The whole process was protected from light [26,31,38,41].

The particle size and zeta potential of the liposome was determined by dynamic light scattering with a particle analyzer (ZS, Malvern, UK). Transmission electron microscopy was carried out with 1% phosphotungstic acid negative staining and visualized using a JEM2010 electron microscope (JEOL, Japan). The peptide-lipid conjugate \( c(RGDyK)-PEG2000-DSPE \) was verified by UV–vis spectrophotometer (Thermo, USA) and mass spectroscopy (Agilent, USA). The stability of RGD-CPGd-L in distilled water and fetal bovine serum (Boster, China) was also monitored by UV–vis spectrophotometer at room temperature.

#### 2.2. Quantification of PTX, Gd-DTPA-BMA and CBP

The content of PTX incorporated in liposome was detected by HPLC (1200 Series, Agilent, USA). Specifically, the liposome was diluted by adding water and acetonitrile to 0.5 mL. PTX was extracted by adding 4.0 mL of tert-butyl methyl ether and mixing for 30 s. The mixture was centrifuged for 15 min at 300g, after which 3 mL of the organic layer was transferred and evaporated. The residue was dissolved with 100 μL of 7/3 acetonitrile/water mixture. 50 μL of the solution was injected into a C18 column guard. The flow rate was 1.0 mL/min. The detection wavelength was set at 227 nm. The drug concentration was calculated from standard curves. This assay was linear over the concentration range from 1 μg to 500 μg [21,29].

The content of Gd-DTPA-BMA and CBP of the liposome were determined by amount of Gd and Pt detected by ICP-AES (IRIS Intrepid II XSP, Thermo, USA) respectively [42]. The sample was diluted with 0.5 mL water before adding 2 mL HNO3 and heated...
to approximately 150 °C for 30 min. Thereafter, the sample was diluted to 10 mL with water. Calibration was done with gadolinium and platinum ICP standard solution [43].

2.3. Characterization of contrast properties

The MR contrast effect of the liposome was examined by measuring the proton longitudinal relaxivity \( r_1 \), of which the definition is the slope of the concentration dependence given as \( 1/T_1 = 1/T_{10} + r_1[Gd] \), where \( T_1 \) is the longitudinal relaxation time, \( T_{10} \) is the longitudinal relaxation time in the absence of paramagnetic substances. The \( T_1 \) of liposome with different concentrations at 25 °C was measured by 500 MHz NMR spectrometer (Avance 500, Bruker, USA) using a standard inversion-recovery pulse sequence. MR images were taken with a 7 T MRI scanner (BioSpec 70/20 USR, Bruker, USA) using 1% agarose phantom to mimic the MRI properties of biological tissue. Different concentrations of liposome were added into the phantom. The \( T_1 \) of liposome with different concentrations at 25 °C was measured by 500 MHz NMR spectrometer (Avance 500, Bruker, USA) using a standard inversion-recovery pulse sequence.

2.4. Cell culture and cancer model

The non-small-cell lung cancer cell A549, H1299 and human embryonic lung fibroblast WI-38 were purchased from the cell bank of Chinese academy of sciences (Shanghai, China). The tumor cells and normal cells were cultured in IMDM (Iscove’s Modified Dulbecco’s Medium, Boster, China) and MEM (minimum essential medium, Boster, China) respectively, supplemented with 10% fetal bovine serum (Boster, China), 100 U/mL penicillin (Boster, China) and 100 U/mL streptomycin (Boster, China) in a humidified air with 5% CO_2 at 37 °C.

BALB/c male nude mice (aged 5–6 weeks, approximately 20 g) were purchased from Human SJA Laboratory Animal Co., Ltd. All experimental protocols in this study were approved by Animal Care and Use Committees at the Wuhan Institute of Physics and Mathematics, the Chinese Academy of Sciences. The mice were inoculated subcutaneously with A549 cells (1 × 10^6 cells of each) on the legs and used for MRI after 1 week breeding.

2.5. In vitro targeting effect

About 1 × 10^5 cells (A549, H1299 and WI-38, respectively) were seeded on cover slips placed in cell culture dishes. The regular culture mediums were removed when the cell confluence reached to 30–40%. Culture medium containing the rhodamine labeled liposome was added. After 4 h of incubation at 37 °C, cells were incubated with DAPI for 5 min for nuclear staining. All the cells were washed at least three times with PBS. The fluorescence images were taken by confocal laser scanning microscope (A1R/A1, Nikon, Japan) [7,29].

2.6. Cytotoxicity assay

About 1 × 10^4 cells (A549, H1299 and WI-38, respectively) were seeded per well in 96-well plates and cultured for 24 h. Different groups of liposomes were diluted with the medium and added to the well. After incubation for 48 h, cells were washed with PBS (pH 7.4) three times. MTT was added to the culture medium to the final concentration of 0.5 mg/mL during the last 4 h. 200 μL DMSO was added per well after removing the medium. The OD 490 nm for each well was measured by ELISA plate reader (Spectra MAX 190, Molecular Devices, USA) [7,34,45].

2.7. In vivo contrast properties

7 T MRI provided monitoring of liposome gathering in tumor-bearing mice by repeat scanning prior to treatment and post-treatment. A549 xenograft mice were oriented in prone position and the legs were fixed. The mice were initially anesthetized with 3% isoflurane, and then 1% isoflurane controlled by Matrx (USA). The respiratory cycle was monitored by a pneumatic pillow. \( T_1 \)-weighted MRIs were obtained before and after tail intravenous administration of the dual drug-loaded liposome and Omniscan (GE Healthcare, Ireland) using a spin-echo technique (TE = 11 ms, TR = 400 ms, 1-mm slice thickness, average = 4, matrix size = 256 × 256, FOV = 4 × 4 cm²) [31,42]. The concentration of Gd was 0.1 mmol/kg both in the liposome and omniscan group.
2.8. Assessment of therapeutic effect by MRI

The therapeutic effect of dual drug-loaded liposome on tumor was evaluated by 7 T MRI scanner. A549 tumor bearing mice were used after 7 days post-tumor inoculation [31]. The fixation and anesthesia process were the same as above. RGD-CPGd-L was injected via tail vein at 500 mg/kg (about 53.10 mg/kg Gd-DTPA-BMA, 4.70 mg/kg PTX and 1.12 mg/kg CBP). The control group was injected with the same volume saline as the medicated group. When testing the tumor volume of control group, the same amount of RGD and 380 mg/kg CBP (sample 1). Demonstrating the enhanced T1 MR contrast property. RGD-CPGd-L displayed good physical stability over 24 h when reconstituted either in water or serum (Fig. 2d), which was beneficial for following experiments. As shown in Table 1, contrast agent and two anticancer drugs with different properties and mechanisms of drug action were successfully encapsulated in the liposome. The concentration of Gd-DTPA-BMA, CBP, PTX of liposome were 106.19 ± 23.53 μg/mg, 2.23 ± 0.37 μg/mg and 9.39 ± 1.71 μg/mg, respectively.

3.2. Lung cancer cell targeting

Three cell lines, including two NSCLC cell lines, A549 and H1299, and a normal cell line, WI-38, were used to test the binding efficiency of the targeted liposome by confocal laser scanning microscopy (CLSM). The RGD peptide has been widely used as a targeting ligand to mediate specific binding to integrin αvβ3, which is overexpressed in many cancer cells [8,9,46]. The c(RGDyK)-modified liposome could be internalized via endocytosis mediated by the αvβ3 integrin receptor [8,34,36]. RGD-CPGd-L was absorbed more than CPGd-L (Fig. 2b) by both cancer cells, indicating the targeting effect of peptide c(RGDyK). As shown in Fig. 3, the red fluorescence intensity of different cells became stronger with increasing incubation time. For NSCLC cells, the fluorescence signals were noticeably strong. The red fluorescence was mainly observed along the cell membranes and within the cytoplasm. The fluorescence intensity of H1299 cells was slightly higher than that of A549 cells, likely resulting from the intrinsic differences between these cell lines, which are known to differ by the density of αvβ3 integrin receptors [47]. In contrast, the observed red fluorescence was much weaker in normal cells WI-38, even for incubation times up to 240 min. The results show a remarkably strong contrast for cancers vs normal cells, which we speculate may be related to the vastly different densities of αvβ3 receptors at the cell surfaces, for these cell lines [26]. These results suggest that this carrier has the potential to increase drug efficiency and decrease side effects in vivo.

3.3. Drug-mediated cytotoxicity

The anticancer efficiency of RGD-CPGd-L was tested in three different cell lines (cancer cell A549, H1299 and normal cell WI-38) by MTT assay. Different liposomes resulted in dose dependent toxicity on the cells (Fig. 4). The c(RGDyK)-modified liposome can target tumor cells and induce apoptosis [9,35,48]. In two cancer cell lines, cell viability was decreased significantly by treatment with RGD-CPGd-L compared to the non-peptide-modified CPGd-L or single drug-loaded liposome CPGd-L or PGd-L (Fig. 3c). Cell viability was 48.30% and 55.86% for H1299 and A549, respectively, when RGD-CPGd-L was dosed at concentration up to 12 mg/mL. The targeted liposome was more effective on H1299 than A549 cells, which was in agreement with the fluorescence results. The αvβ3 receptor and response of different cancer cells can also vary [7,47]. The blank liposome had a negligible effect on all cell lines, even for incubation times up to 240 min. For normal cells, all groups of liposomes had low cytotoxicity, even at high concentrations. Overall, the targeted combination of PTX and CBP demonstrated a synergistic drug effect to tumor cells, which might be superior in cancer treatment.

3.4. In vivo targeted delivery

To evaluate whether such a dual drug-loaded liposome is suitable for in vivo tumor targeting, T1-weighted MRI was carried out on a 7-T MRI small animal imager before and after administration
of RGD-CPGd-L via tail vein to A549 xenograft nude mice. For comparison to a non-specific contrast agent, mice were injected with an equal dose of Omniscan/C210. Fig. 5a clearly demonstrates specific contrast enhancement at the tumor area after administration of the liposome. The tumor of control group also turned bright, but the enhancement was much lower than the case of RGD-CPGd-L. Variations in the spin-lattice relaxation rates $R_1$ can be seen in Fig. 5b. $R_1$ was increased more than 10-fold about 4 h and 36-fold nearly 5 h after administration of the new agent compared with the control group. In contrast to the non-treated mouse, $R_1$ increased about 2.3-fold with the dual drug-loaded liposome. These results demonstrate the targeting effect of the liposome for the tumor site in vivo, which is consistent with the results of in vitro fluorescence and our MTT assay. Besides solving the problem of PTX insolubility in water and the simultaneous administration of PTX and CBP, this liposome can significantly improve the MRI contrast effect, even at a relatively low dose (100 μmol Gd/kg). The signal enhanced by the targeted liposome maintained a high level for more than 5 h, beginning at 1 h after the treatment, and returned to original levels after 24 h, indicating good metabolism and giving the investigator substantial time to acquire detailed scans, establish a diagnosis, and conduct and assess the efficacy of drug therapy. In contrast, the MRI signal within the tumor of the control group (Omniscan injection) decreased after 1 h (Fig. S4). PEG coating can form a protective layer over the liposome surface and slow down the recognition by fopsonins, and the subsequent clearance of the particles [30]. This could lead to longer circulation time and a modulation of the EPR (enhanced permeability and retention) effect [20,42]. The enhanced MRI signal and prolonged acting time of contrast agent implies the higher efficiency of delivering small molecules, better performance of tumor inhibition and lower side effects by RGD-CPGd-L than traditional agents.

3.5. Therapeutic effect monitored by MRI

Further, the antitumor efficiency of this dual drug-loaded liposome was studied in vivo. First, the body weight of mice was monitored to measure the systemic toxicity of this agent (Fig. 6a). Nearly all mice decreased in weight during the first week, followed by a return of both groups to the initial weight and beyond. This result indicated that there was no detectable systemic toxicity of the liposome. Also there was no acute toxicity observed during and after the experiment. The antitumor effect was monitored by MRI over a period of 23 days. The volumes of A549 tumors were significantly reduced

Table 1

<table>
<thead>
<tr>
<th>Size (nm)</th>
<th>PDI</th>
<th>Zeta potential (mV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>128.4 ± 8.1</td>
<td>0.123</td>
<td>-13.8 ± 4.4</td>
</tr>
<tr>
<td>Gd-DTPA-BMA (μg/mg)</td>
<td>CBP (μg/mg)</td>
<td>PTX (μg/mg)</td>
</tr>
<tr>
<td>106.19 ± 23.53</td>
<td>2.23 ± 0.37</td>
<td>9.39 ± 1.71</td>
</tr>
</tbody>
</table>

of RGD-CPGd-L via tail vein to A549 xenograft nude mice. For comparison to a non-specific contrast agent, mice were injected with an equal dose of Omniscan/C210. Fig. 5a clearly demonstrates specific contrast enhancement at the tumor area after administration of the liposome. The tumor of control group also turned bright, but the enhancement was much lower than the case of RGD-CPGd-L. Variations in the spin-lattice relaxation rates $R_1$ can be seen in Fig. 5b. $R_1$ was increased more than 10-fold about 4 h and 36-fold nearly 5 h after administration of the new agent compared with the control group. In contrast to the non-treated mouse, $R_1$ increased about 2.3-fold with the dual drug-loaded liposome. These results demonstrate the targeting effect of the liposome for the tumor site in vivo, which is consistent with the results of in vitro fluorescence and our MTT assay. Besides solving the problem of PTX insolubility in water and the simultaneous administration of PTX and CBP, this liposome can significantly improve the MRI contrast effect, even at a relatively low dose (100 μmol Gd/kg). The signal enhanced by the targeted liposome maintained a high level for more than 5 h, beginning at 1 h after the treatment, and returned to original levels after 24 h, indicating good metabolism and giving the investigator substantial time to acquire detailed scans, establish a diagnosis, and conduct and assess the efficacy of drug therapy. In contrast, the MRI signal within the tumor of the control group (Omniscan injection) decreased after 1 h (Fig. S4). PEG coating can form a protective layer over the liposome surface and slow down the recognition by fopsonins, and the subsequent clearance of the particles [30]. This could lead to longer circulation time and a modulation of the EPR (enhanced permeability and retention) effect [20,42]. The enhanced MRI signal and prolonged acting time of contrast agent implies the higher efficiency of delivering small molecules, better performance of tumor inhibition and lower side effects by RGD-CPGd-L than traditional agents.

3.5. Therapeutic effect monitored by MRI

Further, the antitumor efficiency of this dual drug-loaded liposome was studied in vivo. First, the body weight of mice was monitored to measure the systemic toxicity of this agent (Fig. 6a). Nearly all mice decreased in weight during the first week, followed by a return of both groups to the initial weight and beyond. This result indicated that there was no detectable systemic toxicity of the liposome. Also there was no acute toxicity observed during and after the experiment. The antitumor effect was monitored by MRI over a period of 23 days. The volumes of A549 tumors were significantly reduced
after treatment with dual drug-loaded liposome at day 10 (Fig. 6b). This may be explained by the intense treatment regimen within the first week of therapy. For example, percentage increases of tumor volume were 37.50/50/31.25 and 11.11/38.46/50 for liposome group and control group, respectively, at day 10 of the treatment period. Although the tumors of the liposome group increased in later days, the tumor growth inhibition effect was more obvious than in the control group. The exact tumor variation over time could be clearly seen via T1-weighted MRIs (Fig. 6c). Mice treated with liposomes had significant tumor growth inhibition.
compared to the control ones. Particularly, the tumor could be inhibited greatly when the initial volume was small, just as the tumor of the liposome group from 2 mm$^3$ before treatment to 3 mm$^3$ at the end of the test (Fig. S5). This is a promising result for early cancer or tumor metastasis control. Moreover, the signal of the tumor region could be greatly enhanced by this multifunctional liposome even for tumors as small as 1 mm$^3$ (Fig. S5), demonstrating the efficient targeted delivery of the contrast agent and anti-cancer drugs. Tumor development and therapeutic effect was monitored and evaluated safely and timely by MRI. Further,
the development of drug resistance by tumor cells could be impaired when they are treated simultaneously using dual drugs agents rather than a single one [16]. Dual drugs-loaded systems were seldom be developed and mainly on water soluble drugs, just as busulfan/fludarabine [15], irinotecan/floxuridine [16] and irinotecan/cisplatin [17]. Our liposome, contains both hydrophobic paclitaxel and hydrophilic carboplatin, would broaden the scope of drug-loading system. Besides NSCLC, CBP and PTX doublet chemotherapy can also be used in patients with ovarian cancer [49,50]. Based on the researches about liposomal delivery, our system would be an attractive candidate for NSCLC and other cancer treatments.

The histopathological study did not show any distinct changes in the main organs (liver, kidney and spleen) between the treatment and control groups (Fig. 7), indicating this nanoparticle had a negligible toxic effect on the mice. Because of the active tumor targeting, most of the intact liposome might specifically bind to the tumor, thereby decreasing the side effect of the drugs [41]. These results demonstrate that this liposome can be used as a theranostic agent to study the drug behaviors and monitor the therapeutic effects on tumors using MRI.

4. Conclusions

The combination of therapeutic drugs CBP and PTX, together with the diagnostic agent gadodiamide, within a single platform was successfully developed, thereby realizing the simultaneous application of therapeutics and diagnosis. Cytotoxicity tests demonstrated the synergistic effect of this combination. By way of in vitro fluorescence microscopy and in vivo MRI, this multifunctional liposome could effectively target non-small-cell lung cancer cells. The tumor signal can be greatly enhanced by employing a Gd-DTPA-BMA-loaded liposome in comparison to the commercial contrast agent Omniscan®. Furthermore, based on the nanoparticles with superior MRI contrast properties, the liposome can provide a non-invasive, real-time MRI strategy with excellent tissue depth penetration and significantly improved sensitivity. Tumor growth could be effectively inhibited with the administration of this drugs-loaded liposome. Consequently, the treatment effects can be evaluated in real-time to allow for optimization of treatment strategies, along the lines of delivering more personalized cancer therapies. Overall, this multifunctional targeted drug delivery system, although needs more studies, constitutes a major advance in the application of nanotechnologies in medicine, opening up new possibilities for the diagnosis and treatment of human diseases.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81227902, 21305156 and 21575157).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.actbio.2016.02.011.

References


